ArticleBMC endocrine disorders2026
Factors associated with poor glycaemic control among adults with type 2 diabetes mellitus in Albania: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor glycaemic control is common among adults with type 2 diabetes mellitus (T2DM) in low- and middle-income settings in South-Eastern Europe, yet patient-level data on its correlates from Albania are scarce. We examined the demographic, clinical and treatment-related factors associated with poor glycaemic control (HbA1c ≥ 7%) in Albanian adults with T2DM.
methodsCross-sectional study of 176 consecutive adults with T2DM attending a hospital-based outpatient diabetes service in northern Albania. Poor glycaemic control was defined a priori as HbA1c ≥ 7% (53 mmol/mol). Sociodemographic characteristics, diabetes duration, insulin therapy and physician-confirmed comorbidities were recorded. Associations were assessed using univariate and multivariable logistic regression, estimating odds ratios (OR) with 95% confidence intervals (CI); comorbidity was modelled both as individual conditions (primary model) and as a comorbidity-burden index (sensitivity model). Model calibration and discrimination were evaluated using the Hosmer-Lemeshow test and the area under the ROC curve.
resultsMean age was 65 years, 51% were men and mean diabetes duration was 11 years. The prevalence of poor glycaemic control was 58.5% (95% CI 50.9-65.9%), and 54% were receiving insulin. In univariate analyses, poor control was more frequent with insulin therapy (OR 5.64, 95% CI 2.93-10.87), longer diabetes duration (OR 1.42 per 5 years, 1.09-1.85) and ischaemic heart disease (OR 2.10, 1.09-4.08). After mutual adjustment, insulin therapy was the only factor independently associated with poor control (adjusted OR 6.32, 95% CI 2.71-14.71); age, diabetes duration, hypertension, ischaemic heart disease and multimorbidity were not. Results were unchanged in the sensitivity model. The primary model was well calibrated (Hosmer-Lemeshow p = 0.96), with moderate discrimination (area under the ROC curve 0.74).
conclusionsIn this Albanian outpatient population, poor glycaemic control was common and insulin therapy was the only factor independently associated with it. This reflects confounding by indication rather than harm from insulin: insulin is initiated when oral therapy no longer maintains targets, so insulin-treated patients form a clinically identifiable subgroup with more advanced disease who warrant priority for structured treatment intensification and individualised follow-up. Prospective multicentre studies are needed to confirm these associations and their temporal direction.
trial registrationNot applicable (observational, non-interventional study).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.